These data were strengthened by our in-house SHH-GBM clinical data, which showed that GBM tumors had a higher NEDD4-1 level than their normal tissue counterparts, as demonstrated by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and IHC. Here, NEDD4 is linked to glioblastoma.